Cash and investments in marketable securities at
"We are pleased that the MOVANTIK launch in the U.S. is off to an encouraging start with very rapid uptake," said
Year-to-date revenue for 2015 was
Total operating costs and expenses in the first half of 2015 were
Research and development expense in the second quarter of 2015 was
General and administrative expense was
Net loss in the second quarter of 2015 was
The company also announced the following upcoming presentations and events:
IASLC 16th
- Abstract/Poster Title: "Etirinotecan Pegol (NKTR-102) in the Treatment of Patients with Metastatic Non Small Cell Lung Cancer (NSCLC) after Failure of 2nd Line Treatment: A Phase II study", Aggarwal C., et al.
- Date:
September 9, 2015 ,9:30 a.m. -4:30 p.m. Mountain Time
- Date:
CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference, Translating Science into Survival 2015,
- Abstract/Poster Title: "Antitumor activity of the CD122-biased immunostimulatory cytokine combined with immune checkpoint blockade requires innate and adaptive immunity", Langowski, J., et al.
- Date:
September 18, 2015 ,4:30-6:30 p.m. Eastern Time
- Date:
Nektar Investor and Analyst R&D Day,
- Date:
October 8, 2015 ,12:00-3:30 p.m. Eastern Time
Conference Call to Discuss Second Quarter 2015 Financial Results
This press release and a live audio-only Webcast of the conference call can be accessed through a link that is posted on the home page and Investor Relations section of the
To access the conference call, follow these instructions:
Dial: (877) 881.2183 (U.S.); (970) 315.0453 (international)
Passcode: 97434654 (
In the event that any non-GAAP financial measure is discussed on the conference call that is not described in the press release, or explained on the conference call, related information will be made available on the Investor Relations page at the
About
MOVANTIK™ is a trademark and MOVENTIG® is a registered trademark of the AstraZeneca group of companies.
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will" and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding the potential of MOVANTIK, AstraZeneca's planned commercial launch of MOVANTIK in
Contact:
Investors
Jennifer Ruddock of Nektar Therapeutics
415-482-5585
Media
Nadia Hasan of WCG
212-257-6738
nektar@wcgworld.com
| ||||||
CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||
(In thousands) | ||||||
(Unaudited) | ||||||
ASSETS |
|
|
(1) | |||
Current assets: |
||||||
Cash and cash equivalents |
$ 20,875 |
$ 12,365 |
||||
Restricted cash |
25,000 |
25,000 |
||||
Short-term investments |
233,785 |
225,459 |
||||
Accounts receivable, net |
3,680 |
3,607 |
||||
Inventory |
10,124 |
12,952 |
||||
Other current assets |
8,782 |
8,817 |
||||
Total current assets |
302,246 |
288,200 |
||||
Property, plant and equipment, net |
72,158 |
70,368 |
||||
Goodwill |
76,501 |
76,501 |
||||
Other assets |
5,762 |
6,552 |
||||
Total assets |
$ 456,667 |
$ 441,621 |
||||
LIABILITIES AND STOCKHOLDERS' EQUITY |
||||||
Current liabilities: |
||||||
Accounts payable |
$ 2,833 |
$ 2,703 |
||||
Accrued compensation |
10,824 |
5,749 |
||||
Accrued clinical trial expenses |
8,946 |
7,708 |
||||
Other accrued expenses |
9,713 |
6,418 |
||||
Interest payable |
6,917 |
6,917 |
||||
Capital lease obligations, current portion |
5,643 |
4,512 |
||||
Deferred revenue, current portion |
22,987 |
24,473 |
||||
Other current liabilities |
13,214 |
5,567 |
||||
Total current liabilities |
81,077 |
64,047 |
||||
Senior secured notes |
125,000 |
125,000 |
||||
Capital lease obligations, less current portion |
2,889 |
4,139 |
||||
Liability related to sale of future royalties |
121,971 |
120,471 |
||||
Deferred revenue, less current portion |
73,963 |
76,911 |
||||
Other long-term liabilities |
16,668 |
14,721 |
||||
Total liabilities |
421,568 |
405,289 |
||||
Commitments and contingencies |
||||||
Stockholders' equity: |
||||||
Preferred stock |
- |
- |
||||
Common stock |
13 |
13 |
||||
Capital in excess of par value |
1,841,730 |
1,824,195 |
||||
Accumulated other comprehensive loss |
(1,498) |
(1,567) |
||||
Accumulated deficit |
(1,805,146) |
(1,786,309) |
||||
Total stockholders' equity |
35,099 |
36,332 |
||||
Total liabilities and stockholders' equity |
$ 456,667 |
$ 441,621 |
||||
(1) The consolidated balance sheet at | |||||||||||
| |||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||
(In thousands, except per share information) | |||||||
(Unaudited) | |||||||
Three Months Ended |
Six Months Ended | ||||||
|
| ||||||
2015 |
2014 |
2015 |
2014 | ||||
Revenue: |
|||||||
Product sales and royalty revenue |
$ 11,713 |
$ 5,891 |
$ 19,812 |
$ 11,808 | |||
Non-cash royalty revenue related to sale of future royalties |
4,740 |
4,837 |
8,702 |
10,610 | |||
License, collaboration and other revenue |
6,208 |
17,785 |
102,948 |
25,866 | |||
Total revenue |
22,661 |
28,513 |
131,462 |
48,284 | |||
Operating costs and expenses: |
|||||||
Cost of goods sold |
10,534 |
5,108 |
18,978 |
13,015 | |||
Research and development |
45,412 |
36,702 |
92,423 |
75,040 | |||
General and administrative |
10,184 |
9,619 |
20,487 |
19,547 | |||
Total operating costs and expenses |
66,130 |
51,429 |
131,888 |
107,602 | |||
Loss from operations |
(43,469) |
(22,916) |
(426) |
(59,318) | |||
Non-operating income (expense): |
|||||||
Interest expense |
(4,118) |
(4,488) |
(8,289) |
(9,021) | |||
Non-cash interest expense on liability related to sale of future royalties |
(5,152) |
(5,134) |
(10,202) |
(10,521) | |||
Interest income and other income (expense), net |
246 |
96 |
457 |
408 | |||
Total non-operating expense, net |
(9,024) |
(9,526) |
(18,034) |
(19,134) | |||
Loss before provision for income taxes |
(52,493) |
(32,442) |
(18,460) |
(78,452) | |||
Provision for income taxes |
164 |
195 |
377 |
386 | |||
Net loss |
|
$ (32,637) |
$ (18,837) |
| |||
Basic and diluted net loss per share |
$ (0.40) |
$ (0.26) |
$ (0.14) |
$ (0.63) | |||
Weighted average shares outstanding used in computing basic and diluted net loss per share |
131,643 |
127,040 |
131,502 |
125,301 |
| |||
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | |||
(In thousands) | |||
(Unaudited) | |||
Six Months Ended | |||
2015 |
2014 | ||
Cash flows from operating activities: |
|||
Net loss |
$ (18,837) |
| |
Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | |||
Non-cash royalty revenue related to sale of future royalties |
(8,702) |
(10,610) | |
Non-cash interest expense on liability related to sale of future royalties |
10,202 |
10,521 | |
Stock-based compensation |
9,737 |
8,525 | |
Depreciation and amortization |
5,833 |
6,519 | |
Other non-cash transactions |
(621) |
865 | |
Changes in operating assets and liabilities: |
|||
Accounts receivable, net |
(73) |
(818) | |
Inventory |
2,828 |
(659) | |
Other assets |
190 |
738 | |
Accounts payable |
(10) |
(1,818) | |
Accrued compensation |
5,075 |
(2,868) | |
Accrued clinical trial expenses |
1,238 |
(3,697) | |
Other accrued expenses |
1,859 |
(314) | |
Deferred revenue |
(4,434) |
7,636 | |
Other liabilities |
11,772 |
(6,557) | |
Net cash provided by (used in) operating activities |
16,057 |
(71,375) | |
Cash flows from investing activities: |
|||
Maturities of investments |
111,001 |
118,777 | |
Purchases of investments |
(124,468) |
(166,496) | |
Sale of investments |
5,215 |
- | |
Purchases of property, plant and equipment |
(4,584) |
(5,192) | |
Net cash used in investing activities |
(12,836) |
(52,911) | |
Cash flows from financing activities: |
|||
Payment of capital lease obligations |
(2,484) |
(1,650) | |
Repayment of proceeds from sale of future royalties |
- |
(7,000) | |
Issuance of common stock, net of issuance costs |
- |
116,601 | |
Proceeds from shares issued under equity compensation plans |
7,798 |
7,961 | |
Net cash provided by financing activities |
5,314 |
115,912 | |
Effect of exchange rates on cash and cash equivalents |
(25) |
6 | |
Net increase (decrease) in cash and cash equivalents |
8,510 |
(8,368) | |
Cash and cash equivalents at beginning of period |
12,365 |
39,067 | |
Cash and cash equivalents at end of period |
$ 20,875 |
$ 30,699 | |
Supplemental disclosure of cash flow information: |
|||
Cash paid for interest |
$ 8,320 |
$ 8,622 |
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nektar-therapeutics-reports-financial-results-for-the-second-quarter-of-2015-300124436.html
SOURCE
News Provided by Acquire Media